

AUTOBAHN LABS

Catalyzing Academic Drug Discovery

June 2023



Academia is THE Primary Source of Innovation in Medicine

Cisplatin
Barnett Rosenberg



Co-transformation
Richard Axel
Saul Silverstein



CRISPR
Jennifer Doudna
Feng Zhang



Massachusetts
Institute of
Technology

Xtandi
Michael Jung
Charles Sawyers

UCLA

Avastin
Judah Folkman



Boston
Children's
Hospital

Vorinostat
Ron Breslow
Paul Marks



Memorial Sloan Kettering
Cancer Center

Cell Therapy
Carl June




UNIVERSITY OF PENNSYLVANIA

Hepatitis C
Harvey Alter
Michael
Houghton
Charles Rice



AUTOBAHN
LABS

Pharma companies and biotech investors tend to license/invest at later stages of drug discovery



Traditional Pharma and Biotech Investors
12-18 months from clinic

Autobahn invests early, to de-risk projects and advance new ideas



Basic Research
Target identification
Pathway elucidation

Target validation
HTS, tool compounds
Hit compounds

Lead identification
Lead optimization
Toxicity studies

IND
enabling

Clinical
Development



Autobahn Labs
4-5 years from clinic

Our mission is to address key financing and expertise gaps to create transformative therapies















Autobahn's University Partners



We work exclusively with PIs at our partner universities
through pre-negotiated agreements

We invest in great science, our portfolio spans disease areas and modalities



Program	Disease area	Status at acceptance	Modality	Target Validation	HTS	H2L	LI	LO
AL20.01	Oncology	Validated target	Small molecule					
AL20.02	Hematology	Advanced lead	Biologic					
AL21.02.01	Oncology	Novel target, hits	Small molecule					
AL21.01.01	Muscular	Novel target	Small molecule					
AL21.02.02	Autoimmune	Hits, novel target	Small molecule					
AL21.03.01	Oncology	Novel target, hits	Small molecule					
AL21.04.01	Oncology	Hits, validated target	Small molecule					
AL21.05.01	Hematology	Advanced hits	Small molecule					
AL21.02.03	Oncology	Novel target	Small molecule					
AL21.02.01	Autoimmune	Hits, validated target	Small molecule					
AL22.05.01	Oncology	Novel target	Small molecule					
AL23.04.01	Oncology	Antibody in hand	Biologic					

We are actively seeking to fund new programs

 Active program

 Terminated program

Autobahn's Investors

Samsara BioCapital is a leading life science venture fund focused on creating outstanding companies to advance innovative therapies to patients in need. Samsara's business model supports ongoing strategic investments, allowing the organization to make committed, long-term investments in promising new areas of medicine.




KCK

KCK, Ltd. is a single-family, evergreen fund that invests across a broad range of sectors and in companies of all stages in the US, Europe and Emerging Markets. Investments are flexible and long-term, with a unique focus on technically and scientifically challenging projects.

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The company operates worldwide providing the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic.



Autobahn Invests up to \$5M into a NewCo to Discover Novel Therapeutics



We collaborate with academic founders to drive discovery

We Partner with Academics to Start Therapeutic Programs



Autobahn's "all-in-one" model facilitates drug discovery

Autobahn Labs Team



Brendan O'Leary, PhD
Chief Executive
Officer



Thomas Novak, PhD
Chief Scientific
Officer



Amit Joshi, PhD
Project Team Leader



Suresh Pitram, PhD
Senior Analyst



Dimitre Simeonov,
PhD
Senior Analyst



Dushyant Pathak,
PhD, MBA
Transactions and
Alliances



Mark Slack, PhD
Advisor



Dave Parry, PhD
Advisor



Stephen
Shuttleworth, PhD
Advisor



Rachel Kandel, PhD
Innovation Fellow



Samuel Hatch
Innovation Fellow

We are a team of drug hunters with expertise across therapeutic areas and modalities

Our Extended Team of Advisors



	<p>Srinivas Akkaraju, MD, PhD Board Member Samsara BioCapital</p>		<p>Thomas Hanke, PhD Board Member Evotec</p>		<p>Nety Krishna, PhD Board Member KCK family office</p>		<p>Jim Glasheen, PhD Independent Board Member Clade Therapeutics</p>
	<p>James Larrick, MD, PhD SAB Chair Panorama Research Institute</p>		<p>Bob Stein, MD, PhD SAB member Samsara BioCapital</p>		<p>John Curnutte, MD, PhD SAB member Samsara BioCapital</p>		<p>Katherine Widdowson, PhD SAB member</p>
	<p>Steve Kelsey, MD SAB member Revolution Medicine</p>		<p>Marcos Milla, PhD Advisor Samsara BioCapital</p>		<p>Abe Bassan Board Observer Samsara BioCapital</p>		

Our advisors each have 20-40 years of drug discovery experience

Leveraging Autobahn's relationship with Evotec



Evotec services are provided at **reduced cost**, driving **significant savings** for each program



Target ID +
Validation



Hit
Identification



Sample
Management



Chemistry



DMPK



Research
Informatics



Proteomics +
metabolomics



Reagents



In Vitro
Biology



In Vitro
Pharmacology



Biomarkers



Antibody
Discovery



INDiGO



Integrated
CMC



Integrated
Pre-Clinical
Development



Integrated
Drug Discovery

Integrated drug discovery plan with clear decision points developed at outset

Single point of contact at Autobahn | Access to more than 3,400 scientists | 50% with PhDs

We fund novel therapeutic projects

In-scope

- Novel target biology in need of additional validation
- Innovative leads or distinct approaches targeting well-established, validated biology
- Clear and notable potential synergies with Autobahn's development expertise

Out-of-scope

- Reagents or tools or MedTech
- Stand alone biomarker/ companion diagnostics projects
- Repurposed or "me-too" drugs
- Ultra-rare diseases (<1000/yr)
- Infectious Diseases
- Gene and Cell-based Therapies

Our Diligence Criteria

Scientific Merit

- Novel, compelling science
- Druggability of target and/or pathway
- Level of validation
- Probability of technical success


Impact Opportunity

- Unmet medical need
- Competitive landscape
- Degree of differentiation
- Potential for partnering
- Intellectual Property

Developability

- Relevant/translatable models to achieve preclinical POC
- Ease of clinical POC
- Differentiated Target Product Profile

Our Roadmap to NewCo Formation



Our Differentiation



Pre-negotiated agreements with our partners

Long-term relationships

PIs as founders

Partnership with world-class CRO

Built-in access to **follow-on** funding

We are structured to promote success!



A photograph of a long, straight asphalt road stretching into the distance, flanked by dense trees with vibrant autumn foliage in shades of orange, yellow, and red. The road has a dashed yellow center line and solid white edge lines. The scene is captured from a low angle, looking down the road towards a bright horizon. A semi-transparent dark grey rectangular box is centered over the road, containing white text.

We are committed to helping you
navigate the long path of drug discovery

Together, we can discover transformative therapies!



Brendan O'Leary, PhD
Chief Executive Officer
brendan@autobahn-labs.com



Tom Novak, PhD
Chief Scientific Officer
tom@autobahn-labs.com



Amit Joshi, PhD
Project Team Leader
amit@autobahn-labs.com



Dimitre Simeonov, PhD
Senior Analyst – West Coast
dimitre@autobahn-labs.com



Suresh Pitram, PhD
Senior Analyst – East Coast
suresh@autobahn-labs.com